Conservación para la salvaguardia del patrimonio cultural

Cyclosporine withdrawal 3 months after transplantation can be done safely, reduces the need of cardiovascular risk factor-controlling medication, improves allograft function, and reduces the incidence of CAN.

proefschrift bakker.indd 79

80

References

1 Bennett WM, DeMattos A, Meyer MM, Andoh T, Barry JM: Chronic cyclosporine nephropathy: the Achilles’ heel of immunosuppressive therapy. Kidney Int. 50:1089-1100, 1996

2 Kasiske BL, Chakkera HA, Louis TA, Ma JZ: A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J.Am.Soc.Nephrol. 11:1910-1917, 2000

3 Hollander AA, van Saase JL, Kootte AM, van Dorp WT, van Bockel HJ, van Es LA, van der Woude FJ: Benefi cial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet 345:610-614, 1995

4 MacPhee IA, Bradley JA, Briggs JD, Junor BJ, MacPherson SG, McMillan MA, Rodger RS, Watson MA: Long-term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation. Transplantation 66:1186-1192, 1998 5 Nankivell BJ, Gruenewald SM, Allen RD, Chapman JR: Predicting glomerular fi ltration rate after

kidney transplantation. Transplantation 59:1683-1689, 1995

6 Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad AS, Yamaguchi Y: The Banff 97 working classifi cation of renal allograft pathology. Kidney Int. 55:713-723, 1999

7 Weir MR, Ward MT, Blahut SA, Klassen DK, Cangro CB, Bartlett ST, Fink JC: Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int. 59:1567-1573, 2001

8 Myers BD, Newton L, Oyer P: The case against the indefi nite use of cyclosporine. Transplant. Proc. 23:41-42, 1991

9 Perico N, Ruggenenti P, Gaspari F, Mosconi L, Benigni A, Amuchastegui CS, Gasparini F, Remuzzi G: Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. Transplantation 54:56-60, 1992

10 Paul LC: Chronic allograft nephropathy: An update. Kidney Int. 56:783-793, 1999

11 Opelz G, Dohler B: Cyclosporine and long-term kidney graft survival. Transplantation 72:1267- 1273, 2001

12 Belitsky P, Dunn S, Johnston A, Levy G: Impact of absorption profi ling on effi cacy and safety of cyclosporin therapy in transplant recipients. Clin.Pharmacokinet. 39:117-125, 2000

13 First MR: Expanding the donor pool. Semin.Nephrol. 17:373-380, 1997

14 Mizutani K, Ono Y, Kinukawa T, Hattori R, Nishiyama N, Kamihila O, Ohshima S: Use of marginal organs from non-heart-beating cadaveric kidney donors. Transplantation 72:1376-1380, 2001

proefschrift bakker.indd 80

81

15 Ojo AO, Hanson JA, Meier-Kriesche H, Okechukwu CN, Wolfe RA, Leichtman AB, Agodoa LY, Kaplan B, Port FK: Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J.Am.Soc.Nephrol. 12:589-597, 2001 16 de Fijter JW, Mallat MJ, Doxiadis II, Ringers J, Rosendaal FR, Claas FH, Paul LC: Increased

immunogenicity and cause of graft loss of old donor kidneys. J.Am.Soc.Nephrol. 12:1538-1546, 2001

17 Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK: Long-term survival in renal transplant recipients with graft function. Kidney Int. 57:307-313, 2000

18 West M, Sutherland DE, Matas AJ: Kidney transplant recipients who die with functioning grafts: serum creatinine level and cause of death. Transplantation 62:1029-1030, 1996

19 Arend SM, Mallat MJ, Westendorp RJ, van der Woude FJ, van Es LA: Patient survival after renal transplantation; more than 25 years follow-up. Nephrol.Dial.Transplant. 12:1672-1679, 1997 20 Kreis HA, Ponticelli C: Causes of late renal allograft loss: chronic allograft dysfunction, death, and

other factors. Transplantation 71:SS5-SS9, 2001

21 Sijpkens YW, Doxiadis II, de Fijter JW, Mallat MJ, van Es LA, De Lange P, Zwinderman AH, Westendorp RG, van Kemenade FJ, Bruijn JA, Claas FH, Paul LC: Sharing cross-reactive groups of MHC class I improves long-term graft survival. Kidney Int. 56:1920-1927, 1999

22 Heim-Duthoy KL, Chitwood KK, Tortorice KL, Massy ZA, Kasiske BL: Elective cyclosporine withdrawal 1 year after renal transplantation. Am.J.Kidney Dis. 24:846-853, 1994

23 Meier-Kriesche HU, Ojo AO, Cibrik DM, Hanson JA, Leichtman AB, Magee JC, Port FK, Kaplan B: Relationship of recipient age and development of chronic allograft failure. Transplantation 70:306-310, 2000

24 Sanders CE, Julian BA, Gaston RS, Deierhoi MH, Diethelm AG, Curtis JJ: Benefi ts of continued cyclosporine through an indigent drug program. Am.J.Kidney Dis. 28:572-577, 1996

25 Schnuelle P, van der Heide JH, Tegzess A, Verburgh CA, Paul LC, van der Woude FJ, de Fijter JW: Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J.Am.Soc. Nephrol. 13:536-543, 2002

26 Lipsky JJ: Mycophenolate mofetil. Lancet 348:1357-1359, 1996

27 Mele TS, Halloran PF: The use of mycophenolate mofetil in transplant recipients.

Immunopharmacology 47:215-245, 2000

28 Ojo AO, Meier-Kriesche HU, Hanson JA, Leichtman AB, Cibrik D, Magee JC, Wolfe RA, Agodoa LY, Kaplan B: Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 69:2405-2409, 2000

29 Smak Gregoor PJ, van Gelder T, van Besouw NM, van der Mast BJ, IJzermans JN, Weimar

W: Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction. Transplantation 70:143-148, 2000

proefschrift bakker.indd 81

Early interstitial accumulation of collagen